Reply

Journal of Pediatrics

Volumn 152, Issue 3, 2008, Pages 447-448

  Clyman, Ronald I ^a   Chorne, Nancy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN;

CLINICAL TRIAL; HUMAN; LETTER; LUNG EDEMA; LUNG HEMORRHAGE; LUNG VASCULAR RESISTANCE; MORBIDITY; NONHUMAN; PATENT DUCTUS ARTERIOSUS; PREMATURE LABOR; PRIORITY JOURNAL; RISK FACTOR;

EID: 38949086838     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2007.10.017     Document Type: Letter

References (15)

1. Alpan G., Scheerer R., Bland R., and Clyman R. Patent ductus arteriosus increases lung fluid filtration in preterm lambs. Pediatr Res 30 (1991) 616-621
2. McCurnin D.C., Seidner S.R., Edde E.L., Cox W.L., Correll D.M., and Coalson J.J. Effects of early indomethacin on postsurfactant pulmonary hemorrhage in preterm baboons with respiratory distress syndrome. [abstract]. Pediatr Res 37 (1995) 342A
3. Domanico R.S., Waldman J.D., Lester L.A., McPhillips H.A., Catrambone J.E., and Covert R.F. Prophylactic indomethacin reduces the incidence of pulmonary hemorrhage and patent ductus arteriosus in surfactant treated infants <1250 grams. [abstract]. Pediatr Res 1994 (1994) 331A
4. Raju T.N.K., and Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: a meta-analysis. J Pediatr 123 (1993) 603-610
5. Alpan G., and Clyman R.I. Cardiovascular effects of surfactant replacement with special reference to the patent ductus arteriosus. In: Robertson B., and Taeusch H.W. (Eds). Surfactant Therapy for Lung Disease: Lung Biology in Health and Disease (1995), Marcel Dekker, New York 531-545
6. Garland J., Buck R., and Weinberg M. Pulmonary hemorrhage risk in infants with a clinically diagnosed patent ductus arteriosus: a retrospective cohort study. Pediatrics 94 (1994) 719-723
7. Kluckow M., and Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage. J Pediatr 137 (2000) 68-72
8. Lin T.W., Su B.H., Lin H.C., Hu P.S., Peng C.T., Tsai C.H., et al. Risk factors of pulmonary hemorrhage in very-low-birth-weight infants: a two-year retrospective study. Acta Paediatr Taiwan 41 (2000) 255-258
9. Fowlie P.W., and Davis P.G. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev (2002) CD000174
10. Bada H.S., Green R.S., Pourcyrous M., Leffler C.W., Korones S.B., Magill H.L., et al. Indomethacin reduces the risks of severe intraventricular hemorrhage. J Pediatr 115 (1989) 631-637
11. Al Faleh K., Smyth J., Roberts R., Solimano A., Asztalos E., and Schmidt B. Prevention and 18-month outcome of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms (TIPP) [abstract]. Pediatr Res 55 (2004) 456A
12. Couser R.J., Ferrara T.B., Wright G.B., Cabalka A.K., Schilling C.G., Hoekstra R.E., et al. Prophylactic indomethacin therapy in the first twenty-four hours of life for the prevention of patent ductus arteriosus in preterm infants treated prophylactically with surfactant in the delivery room. J Pediatr 128 5 Pt 1 (1996) 631-637
13. Setzer-Bandstra E., Montalvo B.M., Goldberg R., Pacheco I., Ferrer P.L., Flynn J., et al. Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants. Pediatrics 82 (1988) 533-542
14. Cotton R.B., Stahlman M.T., Berder H.W., Graham T.P., Catterton W.Z., and Kover I. Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants. J Pediatr 93 (1978) 647-651
15. McCurnin DC, Seidner S, Chang LY, Waleh N, Ikegami M, Petershack JA, et al. Ibuprofen-induced ductus arteriosus closure: physiological, histological and biochemical effects on the premature lung. Pediatrics, in press.